dc.contributor.author |
Schiaffino Salazar, Francesca |
|
dc.contributor.author |
Platts-Mills, James |
|
dc.contributor.author |
Kosek, Margaret N. |
|
dc.date.accessioned |
2019-08-08T15:23:45Z |
|
dc.date.available |
2019-08-08T15:23:45Z |
|
dc.date.issued |
2019 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/7135 |
|
dc.description.abstract |
Purpose of review: To review recent findings regarding the control and treatment of campylobacteriosis. Recent findings: The application of improved diagnostics has led to an upward shift in the attributable burden of Campylobacter infections, in both the United States and Europe as well as in resource-poor settings. Increased focus has brought a fundamental feature of campylobacteriosis - the ability to cause relapsing disease back into focus, and expanding data on antimicrobial resistance has lead from a switch in first-line therapy for severe diarrhea from quinolones to azithromycin in most contexts, even as evidence of expanding macrolide resistance emerges. Summary: Campylobacter spp. infection is a common infection worldwide. Antibiotic-resistant Campylobacter spp. has become an emerging threat with the increase in industrial poultry production, as well as the broad use of antibiotics in both animals and humans. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Wolters Kluwer Health |
|
dc.relation.ispartofseries |
Current Opinion in Infectious Diseases |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
antimicrobial resistance |
en_US |
dc.subject |
Campylobacter spp. |
en_US |
dc.subject |
One Health |
en_US |
dc.subject |
vaccines |
en_US |
dc.title |
A One Health approach to prevention, treatment, and control of campylobacteriosis |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1097/QCO.0000000000000570 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.relation.issn |
1473-6527 |
|